Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors

Advanced uterine leiomyosarcoma (ULMS) is an incurable disease. A significant percentage of cases of ULMS express estrogen and/or progesterone receptors (ER and/or PR). To the authors' knowledge, the role of estrogen suppression in disease management is not known.

[1]  G. Demetri,et al.  Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  J. Blay,et al.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.

[3]  R. Barakat,et al.  Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma. , 2012, Gynecologic oncology.

[4]  A. Italiano,et al.  Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  A. Iasonos,et al.  Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. , 2010, Gynecologic oncology.

[6]  D. Timmerman,et al.  Clinical management of uterine sarcomas. , 2009, The Lancet. Oncology.

[7]  J. Blay,et al.  Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. J. de la Cruz,et al.  Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Franchi,et al.  Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). , 2008, European journal of cancer.

[10]  A. Santin,et al.  Metastatic Uterine Leiomyosarcoma Regression Using an Aromatase Inhibitor , 2007, Obstetrics and gynecology.

[11]  I. Ray-Coquard,et al.  Aromatase inhibitors (AI) are highly effective in uterine sarcomas (US) expressing estrogen receptors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Goldblum,et al.  Estrogen and Progesterone Receptor Expression in Uterine and Extrauterine Leiomyosarcomas: An Immunohistochemical Study , 2004, Applied immunohistochemistry & molecular morphology : AIMM.

[13]  A. Olshen,et al.  Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma , 2004, Cancer.

[14]  E. Perez,et al.  A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. , 2004, The New England journal of medicine.

[15]  E. Perez,et al.  A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer , 2003 .

[16]  O. S. Nielsen,et al.  Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. , 2002, European journal of cancer.

[17]  A. Buzdar,et al.  Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Jack Cuzick,et al.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. , 2008, The Lancet. Oncology.

[19]  R. Mannel,et al.  Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. , 2008, Gynecologic oncology.

[20]  S. Leodolter,et al.  Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters. , 2003, Anticancer research.

[21]  J. Benda,et al.  Female genital tract cancer , 1995, Cancer.